MedTrace Logo

A Clinical Trial to Assess the Safety and Immunogenicity of Nanocovax in Heathy Volunteers

NCT04683484 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 620

Last updated 2020-12-29

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability, and immunization of Nanocovax in healthy volunteers.

Conditions

Interventions

BIOLOGICAL

Nanocovax

Recombinant Protein spike (s) SARS-CoV-2 and adjuvant (0,5 mg Al PO4)

BIOLOGICAL

Placebo

0,5 mg Al PO4

Sponsors & Collaborators

  • Nanogen Pharmaceutical Biotechnology Joint Stock Company

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-10
Primary Completion
2021-06-10
Completion
2021-08-10

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04683484 on ClinicalTrials.gov